Welcome to our dedicated page for Heron Therapeutics SEC filings (Ticker: HRTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Heron Therapeutics, Inc. filings document financial results, governance matters, executive compensation arrangements, and capital-structure actions for a commercial-stage biotechnology company. Recent Form 8-K reports furnish quarterly and annual operating results, preliminary revenue disclosures, business updates for the Acute Care franchise, and material corporate events.
Proxy and governance filings cover director elections, board committee matters, executive pay, equity-award disclosure, and stockholder voting. Other filings record amendments to employment and change-in-control provisions, board appointments, and stockholder approvals tied to potential common-stock issuance from convertible senior unsecured promissory notes and Series A Convertible Preferred Stock.
Heron Therapeutics EVP and CFO Ira Duarte exercised restricted stock units into common shares in a compensation-related transaction. On April 30, 2026, Duarte converted 13,535 and 11,694 restricted stock units into the same number of Heron Therapeutics common shares, with no open-market sales reported. Footnotes explain each restricted stock unit represents a right to receive one common share and that 216,562 RSUs granted in January 2026 vest in 16 equal quarterly installments, highlighting an ongoing, time-based equity compensation program.
Heron Therapeutics Chief Executive Officer Craig A. Collard exercised restricted stock units into common stock in a compensation-related transaction. He acquired 50,021 shares and 34,789 shares of common stock upon conversion of RSUs, reflecting previously granted equity awards that vest over time rather than open-market purchases or sales. Collard’s RSU program includes a grant of 800,337 units that vest in 16 equal quarterly installments beginning after the January 30, 2026 date of grant. Footnotes also note 11,023 shares acquired under the company’s Employee Stock Purchase Plan on April 30, 2026.
Heron Therapeutics, Inc. is asking stockholders to vote at its virtual 2026 annual meeting on June 11, 2026. Stockholders will elect seven directors, ratify Withum Smith+Brown as auditor, and cast an advisory vote on 2025 executive pay.
The company is also seeking approval to amend and restate its 2007 Equity Incentive Plan to add 16,560,000 additional shares and to amend its Employee Stock Purchase Plan to add 10,000,000 shares, expanding equity available for employees and directors. Another advisory proposal asks stockholders to ratify the company’s Tax Benefits Preservation Plan.
The proxy describes Heron’s board structure, committee memberships, governance policies, and key shareholders. As of April 14, 2026, there were 188,638,866 common shares outstanding. It also details a 2025 private placement and a $35.0 million senior unsecured convertible note issuance with major existing investors.
Heron Therapeutics executive William P. Forbes exercised restricted stock units into common shares in a routine compensation-related move. On April 19, 2026, he converted 3,874 restricted stock units, receiving the same number of common shares at a stated price of $0.00 per share, reflecting vesting rather than an open-market purchase or sale.
Following this transaction, Forbes directly held 185,647 shares of common stock and 27,120 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of common stock, and the units vest in 16 equal quarterly installments beginning one quarter after the January 19, 2024 grant date.
Heron Therapeutics Chief Executive Officer Craig A. Collard exercised restricted stock units into common shares as part of his equity compensation. He converted 13,797 restricted stock units into 13,797 shares of common stock at a stated price of $0.00 per share.
After the transaction, he directly holds 662,052 shares of common stock and 96,758 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of common stock and vests in 16 equal quarterly installments beginning one quarter after the January 19, 2024 grant date.
Heron Therapeutics EVP and CFO Ira Duarte exercised restricted stock units to receive additional common shares as equity compensation. On this date, 3,874 restricted stock units converted into 3,874 shares of common stock at a stated price of $0.00 per share.
Following the transaction, Duarte directly held 215,876 shares of common stock and 27,120 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of common stock and vests in 16 equal quarterly installments beginning one quarter after the January 19, 2024 grant date.
A footnote also notes that Duarte’s holdings include 16,646 shares acquired under the Heron Therapeutics, Inc. 1997 Employee Stock Purchase Plan on April 30, 2025, highlighting ongoing participation in both stock purchase and equity award programs.
Heron Therapeutics, Inc. is soliciting proxies for its 2026 Annual Meeting to be held remotely on June 11, 2026 to elect seven directors and vote on six proposals. Material votes include approval to increase equity from the 2007 Amended and Restated Equity Incentive Plan by 16,560,000 shares and to amend the ESPP to add 10,000,000 shares. The record date for voting was April 14, 2026, when 188,638,866 shares were outstanding. The proxy also seeks ratification of Withum as auditor, a nonbinding say-on-pay for 2025 executive compensation, and ratification of the Tax Benefits Preservation Plan. The proxy discloses related-party financing in 2025, including a private placement and issuance of senior unsecured convertible notes due 2031.
Heron Therapeutics Chief Executive Officer Craig A. Collard exercised 62,500 restricted stock units into 62,500 shares of common stock. The RSUs carried a $0.0000 exercise price and each unit represented a right to receive one share of common stock.
After the transaction, Collard directly owned 648,255 shares of Heron Therapeutics common stock. His holdings include 14,045 shares acquired under the Heron Therapeutics, Inc. 1997 Employee Stock Purchase Plan on April 30, 2025. The restricted stock units vest in four equal annual installments beginning one year after the grant date, contingent on his continued service.
Heron Therapeutics, Inc. updated employment and retention arrangements for its senior leadership team. CEO Craig Collard’s amended agreement increases severance protections and equity vesting if he is terminated without cause or resigns for good reason, including enhanced cash payments, accelerated stock vesting and extended company-paid health coverage, with larger benefits during a change in control window. The company also amended and restated management retention agreements for its CFO, Chief Development Officer and Chief Operating Officer, aligning their severance, change in control equity vesting, and 24‑month non‑competition and non‑solicitation covenants, and updating bonus, arbitration and North Carolina governing law provisions.